MacroGenics to Participate in Upcoming Investor Conferences
January 11, 2021 08:45 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Jan. 11, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
MacroGenics Announces FDA Approval of MARGENZA™ for Patients with Pretreated Metastatic HER2-Positive Breast Cancer
December 16, 2020 16:30 ET
|
MacroGenics, Inc.
MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® (trastuzumab), both combined with chemotherapy, in a head-to-head...
Way2Grow (W2G) Biopharma Company Enters Cannabis Productivity and Announces Plans to Seek Health Canada Approval for Magic Mushroom (Psilocybin and Psilocin) Dealer and Research Licencing
December 15, 2020 08:17 ET
|
Way2Grow Nurseries
OSOYOOS, British Columbia, Dec. 15, 2020 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, is pleased to announce it is...
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings
December 14, 2020 08:07 ET
|
Cybin Inc.
--Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications-- --Adelia brings a range of technologies related to novel...
Way2Grow (W2G) Biopharma Company Receives Health Canada Standard Cultivation License, Processing License and Medical Sales License
December 08, 2020 08:17 ET
|
Way2Grow Nurseries
OSOYOOS, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via CannabisNewsWire – Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately owned biopharma company, is pleased to announce that it has...
MacroGenics and EVERSANA Announce Agreement to Support the Potential Launch and Commercialization of Margetuximab
November 30, 2020 16:30 ET
|
MacroGenics, Inc.
MacroGenics accesses EVERSANA’s full suite of commercial services for which both parties share expensesEVERSANA may earn revenue share payments over five years subject to predefined capMacroGenics’...
MacroGenics Announces Achievement of $25 Million in Milestones Related to Retifanlimab Collaboration with Incyte
November 30, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 30, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
November 16, 2020 12:48 ET
|
Processa Pharmaceuticals Inc.
HANOVER, MD., Nov. 16, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing...
MacroGenics to Participate in Upcoming Investor Conferences
November 09, 2020 17:00 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 09, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...
MacroGenics Announces Date of Third Quarter 2020 Financial Results Conference Call
October 28, 2020 16:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal...